NL-OMON42744已完成2 期
A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination with Tremelimumab in Patients with Metastatic Pancreatic Ductal Adenocarcinoma - ALPS
Astra Zeneca0 个研究点目标入组 14 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 14
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1.Histologically or cytologically confirmed metastatic PDAC, no more than 1 prior chemotherapy regimen
- •2. ECOG 0 or 1
- •3. At least 1 lesion, not previously irradiated, that can be accurately measured at
- •baseline as *10 mm in the longest diameter (except lymph nodes, which must have short axis *15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI) scan and that is suitable for accurate repeated measurements
排除标准
- •1.Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer
- •2. History of leptomeningeal carcinomatosis
- •3. Ascites requiring intervention
- •4. Brain metastases or spinal cord compression.
研究者
相似试验
进行中（未招募）
1 期
Study of MEDI4736, when used alone or in combination with Tremelimumab, as second line chemotherapy in metastatic Pancreatic Ductal AdenocarcinomaAdult patients (aged =18 years) with histologically or cytologically confirmed metastatic PDAC, and had tumor progression following prior standard first-line 5-FU-containing or gemcitabine-containing chemotherapy.MedDRA version: 18.0Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticSystem Organ Class: 100000004864EUCTR2015-002001-11-DEAstraZeneca AB130
进行中（未招募）
1 期
Study of MEDI4736, when used alone or in combination with Tremelimumab, as second line chemotherapy in metastatic Pancreatic Ductal AdenocarcinomaEUCTR2015-002001-11-NLAstraZeneca AB130
已完成
2 期
Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal CarcinomaMetastatic Pancreatic Ductal AdenocarcinomaNCT02558894AstraZeneca65
进行中（未招募）
1 期
An open-label, multi-center, phase I/II study of MFA-370 in patients with metastatic urothelial cancerEUCTR2021-000068-30-SEEctin Research AB50
进行中（未招募）
1 期
An open-label, multi-center, phase I/II study of MFA-370 in patients with metastatic urothelial cancerMetastatic urothelial cancerMedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2021-000068-30-LTEctin Research AB50